Related Post
-
Thursday, Gilead Sciences Inc (NASDAQ: GILD) reported Q3 earnings diminished 5% Y/Y to $7.04 billion, which defeat normal analyst estimates of $6.12 billion. The corporation described quarterly earnings of $1.90 per share, which defeat typical estimates of $1.48 for each share.
-
Gilead enhanced its total-calendar year products profits outlook to $25.9-$26.2 billion. The business also raised FY EPS direction from $2.90-$3.30 to $3.35-$3.55.
-
Truist raised the price tag concentrate on for GILD from $76 to $91 with the score upgraded from Hold to Acquire, expressing expectations exceeded with differentiated oncology asset.
-
The analyst claims that Arcus Biosciences Inc (NYSE: RCUS)/GILD triplet will operate in oncology. It sees continuous dollars stream from its COVID drug, Veklury. Truist also notes enhanced gross margin with growth from Biktarvy and Descovy in the near phrase.
-
RBC Capital Markets says the solid quarter was pushed by demand from customers, not just Veklury, showcasing the possible of the company’s core HIV and oncology corporations.
-
RBC elevated the price goal from $79 to $82 with an Outperform ranking.
-
Raymond James notes that Gilead’s HIV company remains strong, pushed predominantly by increased desire and favorable pricing dynamics for Biktarvy. Administration estimates Biktarvy is capturing almost half of the U.S. HIV market, and the all round industry will go on rising by ~2% annually in U.S. and EU.
-
Needham awaits even more maturation of the oncology/mobile treatment pipeline. Manage Keep.
-
Cost Action: GILD shares are up 8.90% at $76.46 on the previous check out Friday.
Hottest Ratings for GILD
|
Date |
Company |
Action |
From |
To |
|---|---|---|---|---|
|
Mar 2022 |
Barclays |
Maintains |
Underweight |
|
|
Mar 2022 |
RBC Cash |
Maintains |
Outperform |
|
|
Feb 2022 |
BMO Cash |
Downgrades |
Outperform |
Current market Complete |
View Extra Analyst Rankings for GILD
See the Most recent Analyst Rankings
See far more from Benzinga
Never overlook actual-time alerts on your shares – be a part of Benzinga Pro for no cost! Test the device that will assist you commit smarter, more rapidly, and better.
© 2022 Benzinga.com. Benzinga does not give financial commitment information. All legal rights reserved.
